Introduction
============

Small cell lung carcinoma accounts for 15% of lung cancer, and the prognosis is poor. Concurrent chemotherapy is the standard treatment modality in limited-stage disease. Moreover, about 50% patients will finally improve brain metastasis during the course of their disease [@B1].

PCI has been regarded as a part of standard care for all SCLC patients in complete remission after initial treatment, including chemoradiotherapy, RT and CRT, since the meta-analysis published in 1999[@B2]. The meta-analysis found that PCI could not only significantly reduce the BM incidence, but also was associated with improved disease-free survival and overall survival, compared with the control group. The findings have been then confirmed by other following clinical studies [@B3]-[@B6]. Now, the guideline has recommended that PCI should be conducted in the SCLC patients who have good responses to the first-line treatment, including complete remission and partial remission [@B7]. However, the patients in most studies received chemotherapy or thoracic radiation therapy as initial treatment.

Surgery has a minor role in the SCLC treatment, for those early-staged SCLC, including T1\~3N0M0[@B8], [@B9]. However, in clinical practice, whether to perform PCI for those resected patients is still not well answered, especially for stage I patients T1-2N0M0[@B10], [@B11], since the recommendation of PCI was based on the meta-analysis of patients received chemotherapy combined with thoracic radiotherapy. In fact, several retrospective studies have long ago noticed that BM incidence was relatively lower in those operable p-stage I SCLC patients, and questioned the validity of PCI in those patients [@B12]-[@B15]. Then very recently, two clinical studies from China reported that p-stage II-III might gain benefits from PCI but not for p-stage I SCLC patients [@B16], [@B17]. However, all these studies were retrospective studies with small number of samples, which limited the reliability of the conclusion.

Since few patients have undergone surgery, random clinical trials are difficult to be carried out, to resolve the role of PCI in resected SCLC. Therefore, we conducted a systematic review with meta-analysis on the effect of PCI in resected SCLC patients, to increase the statistical power of the results and provide more evidence for clinical decision.

Methods
=======

Publication selection
---------------------

Relevant studies were identified from PubMed databases from 1956 to December 2016, the key words were \'small cell lung cancer\' or \'SCLC\' combined with \'PCI\' or \'prophylactic cranial irradiation\'. We did not use \'resection\' or \'surgery\' as key words, to maximize the results. Our literature selection was limited in English. References in the identified publications were also reviewed to find more relevant studies.

Inclusion criteria
------------------

To be included in our meta-analysis, the studies should meet the following criteria: 1) the research objects were SCLC patients received complete resection as the initial treatment for primary tumor; 2) the intervention approach was PCI, 3) The endpoints included overall survival (OS), progression free survival(PFS) and brain metastasis rate; 4) quantitative data on the effect of PCI on the endpoints can be obtained. We also included the studies describing the BM rates in the stage I patients without PCI.

Data extraction
---------------

We extracted the following information from each included article: author\'s name, publication year, accrual duration, follow-up time, number of total patients, number of patients received PCI, patients stage and treatment methods. For survival analysis, HR (hazard ratio) is the most proper statistic to analyze time-event outcomes, which takes both the number and timing of events into consideration. Thus, the multivariable adjusted HR with its 95% CIs was extracted from each original study. However, in some studies, HRs were not reported while Kaplan-Meier survival curves were presented. In this situation, HRs were calculated from data, which were obtained from the survival curves using Engauge Digitizer version 2.11 (free software downloaded from <http://sourceforge.net>), according to the methods described previously [@B18].

Statistical methods
-------------------

The heterogeneity across studies was evaluated by the Cochran\'s Q and*I*^2^ statistics, P \< 0.10 was considered to be statistically significant [@B19]. In the case, the random effects model was used to pool the individual HR estimates [@B20], otherwise, the fixed-effects model was employed. The BM rates were calculated with the variance stabilizing double arcsine transformation[@B21], and then were pooled by the inverse variance heterogeneity model[@B22], thus, studies with incidence of zero could be included in the analysis, and negative lower 95% confidence intervals were avoided[@B23]. Results were back-transformed to natural proportions, for ease of interpretation.

A sensitivity analysis was carried out to examine the stability of the results, in which each study was removed. Publication was investigated by Egger test, P\< 0.1 was considered as statistically significant [@B24]. Meta-analysis of HRs and sensitivity analysis were performed using STA TA12.0 software (Stata Corporation, College Station, TX, USA), and individual rates were pooled using R Version 3.3.2 (<https://www.r-project.org/>).

Results
=======

Study selection and patient characteristics
-------------------------------------------

In total, and 4 retrospective studies concerning on the effect of PCI on overall survival of complete resected SCLC were included, no random clinical trials were identified. In addition, 6 studies described the BM incidence in the resected SCLC patients without PCI [@B12], [@B14]-[@B17], [@B25]. The flowchart of study selection was shown in Figure [1](#F1){ref-type="fig"} and the main characteristics of included studies were shown in Table [1](#T1){ref-type="table"}.

The patient number ranged from 154 to 954. All patients were histologically confirmed small cell lung cancer, and underwent surgical resection as initial treatment. The pathological stages ranged from I-IV, most patients also received adjuvant therapy, including chemotherapy, thoracic irradiation or chemoradiation. Only a small part of patients (17.80%) underwent PCI. The irradiation dose was between 25Gy/10F to 30Gy/10f.

To our knowledge, Ichinose Y, firstly in 1989 reported the BM rate in patients underwent surgical resection, 18% (2/11) p-stage I developed brain metastasis, however, brain CT/ MRI were not used in clinical practice, some patients might have subclinical lesions before treatment [@B25]. Several subsequent studies reported much lower BM rates in p-stage I, compared to II/III patients, including 3 studies from Japan [@B12], [@B14], [@B26], and 1 study from China[@B15], suggesting that PCI might be omitted for patients with p-stage I SCLC.

In 2007, Bischof, et al. explored the effect of PCI on the survival in 39 surgically treated patients with p-stages I and II [@B27]. They found that brain metastasis-free survival (p = 0.01) and overall survival (p = 0.01) were improved significantly in p stage I-II resected patients who received PCI, the incidence of BM was 22% (4/18) and 0.0% (0/21) in the groups without PCI or after PCI, the authors concluded that PCI should be suggested for those surgically treated patients, since they might be also considered in complete remission. However, the authors did not conduct sub-group analysis in p-stage I patients, duo to a small number of sample.

Then, one retrospective study from China by Zhu H, et, al in 2014 showed that no survival benefit was brought from PCI in p-stage I disease, and the 3-year BM rate was only 9.7%[@B16]. Up to now, the largest study using the National Cancer Data Base (NCDB), including 954 patients, found that PCI after surgery and adjuvant chemotherapy was associated with better survival in p-stage I patients, and provides further evidence to support NCCN recommendations on PCI. However, the major limitations of the study included selection bias, confounding variables, inaccurate staging, lack of brain imaging and no data on chemotherapy [@B28], [@B29]. Recently, Xu, J, et al. drew different conclusions in 954 patients with completely resected pT1-2N0M0 SCLC, they found that PCI was associated with a significant survival advantage in patients with completely resected SCLC, but not in patients stage I disease[@B17].

Over Survival
-------------

There were 4 studies [@B16], [@B17], [@B28], [@B30] involving the data of PCI on the survival. HR cannot be acquired for the study by Bischof, et.al [@B27]. However, 3 studies included all the patients who received complete resection, one study [@B28] only included p-stage I patients, which was thus removed from our analysis. Combined analysis by random-effects model showed that the pooled HR was 0.52 (95% CI: 0.33-0.82), with a moderate heterogeneity (*I^2^*= 48.4%, P-heterogeneity= 0.14), indicating that PCI might improve OS in resected SCLC patients (Figure [2](#F2){ref-type="fig"}).

To solve the dispute on the role of PCI in p-stage I SCLC patients, we further conducted subgroup analysis. 2 studies directly provided the HRs on the effect of PCI on OS in p-stage I SCLC patients [@B17], [@B28], another HR was calculated from the Kaplan-Meier survival curve in the study by Zhu H, et al [@B16]. After combining all the results, the summary HR was 0.87 (95% CI: 0.34-2.24), with a substantial heterogeneity (*I^2^*= 65.7%, P-heterogeneity=0.05) (Figure [3](#F3){ref-type="fig"}).

Brain metastasis
----------------

Three studies [@B16], [@B17], [@B30] reported the data of brain metastasis rate comparing patients with PCI to patients without PCI during the follow-up. Our analysis of the 3 studies yielded a pooled RR of 0.50 (95%CI: 0.32-0.78), with no heterogeneity (I^2^= 0.0%, P-heterogeneity= 0.40), suggesting that PCI might reduce the BM incidence significantly in SCLC patients after complete surgery (Figure [4](#F4){ref-type="fig"}).

With respect to the effect of PCI on BM rate in the p-stage I patients, no enough data can be obtained. Only one study by Xu J et, al. reported that the frequency of BM was 10.5% (2/19) in the PCI-treated group while 13.6% (8/59) patients in the non-PCI group developed BM, and the difference between the two groups was not significant (P=0.38)[@B17].

To better explore the role of PCI in p-stage I SCLC patients, we further conducted a meta-analysis of BM incidence in p-stage I SCLC patients who did not undergo PCI. A total of 6 studies reported the BM incidence in those populations. Wu, A. J.et al. recently reported that the 5-year cumulative incidence of brain metastasis for stage I/II and III were 12% and 26% in a review of 283 patients, which was not included in our analysis, since the BM rates of I and II stage patients were combined together[@B31]. After combining all the results, a low metachronous BM incidence (0.12, 95% CI: 0.08-0.17) was observed, with no heterogeneity (I^2^= 0.0%, P-heterogeneity=0.79) (Figure [5](#F5){ref-type="fig"}).

Sensitivity analysis and Publication bias
-----------------------------------------

Sensitivity analysis showed that the pooled HRs were not changed significantly, when one study was removed and the rest were analyzed, which supported the reliability of our results. Since the small number of the studies included, publication bias was not evaluated by Egger\'s test or Begg\'s test. However, the funnel plot on the BM incidence seemed symmetrical (Supplementary Figure [1](#SM0){ref-type="supplementary-material"}), indicating that there was no significant publication bias in the meta-analysis.

Discussion
==========

According to our knowledge, this is the first meta-analysis concerning the influence of PCI on the survival in resected SCLC patients. Our results indicated that PCI might provide benefits for those complete resected SCLC patients as a whole, however, for p-stage I patients, PCI seemed to be useless for improving OS, since the BM incidence was relatively low in those patients.

Surgery can be an option for very early limited-stage SCLC, especially clinical stage I.

(T1-2N0) SCLC patients. However, the role of PCI in those patients has not been investigated sufficiently, due to the small number of patients involved [@B32]. The controversy has been lasted to very recently, favorers insisted that R0 resection can be considered as a special form of complete remission, and thus PCI is also suitable for those patients [@B33], opponents argued that BM incidence was quite low in these early-stage patients, and neurological effects brought by PCI might outweigh its possible benefits [@B10]. The focus of the debate is the value of PCI in p-stage I patients. Basing on the published clinical studies, our results indicated that PCI might improve OS and reduce BM rate significantly in the complete SCLC patients.

To resolve the debate in p-stage I patients, our subgroup analysis showed that PCI was not associated with longer OS in this group. Only one study reported the difference of BM rates between PCI-group and non-PCI group, which found the result was non-significant. Therefore, we further performed a quantitative meta-analysis of BM incidence rates in p-stage I patients, and the results revealed that approximately 10% of p-stage I SCLC patients developed brain metastasis, indicating that no survival advantage obtained from PCI in p-stage I SCLC patients might be caused by the low incidence of BM in this population, and our result was similar to one brief report by Eze, C, et al [@B29]. In fact, previous studies found the BM rate in advanced-stage NSCLC was even higher (18-25%) , and PCI did not improve OS or DFS, although decreased the risk of BM[@B34], [@B35]. Therefore, PCI is not recommended as routine treatments for those patients, since cranial irradiation is potentially associated with a higher risk neurocognitive injury [@B36], which might overweight the potential benefits from PCI.

However, some shortcomings must be admitted in our meta-analysis. Firstly, since only few SCLC patients undergo surgical resection, there are still no random clinical studies to investigate the use of PCI in those patients. The studies included in our meta-analysis are retrospective studies with a small number of patients, which are prone to recall and selection bias. However, low heterogeneity was observed in our study, indicating the consistency among original studies. Secondly, lack of individual patient data limited our further analysis, especially the relative risks of 2-year OS and 5-year OS, also more subgroup analyses stratified by age, ethnicity, pathological stage and use of chemotherapy were not performed, Lastly, only publications in English were included, and meeting abstracts, trial registries, and articles in other languages were not retrieved, possible publication bias was inevitable.

Surgical resection is also recommended by the current guideline for early-stage small cell lung cancer, however, rigorous examinations before surgery including thoracic CT, PET/CT, brain MRI are necessary [@B37]. Although our results did not support the routine employment of PCI in pT1-2N0M0 stage SCLC patients, the decision of individual treatments must be established by the multidisciplinary team discussion and adequate communication with patients. For those patients, close surveillance with brain MRI may be an alternative strategy.

Conclusions
===========

In conclusion, our results suggest that PCI might be associated with a favorable survival advantaged and reduced BM risk in complete resected SCLC patients, except for p-stage I patients. Given the small number of included studies, the finding should be further confirmed by well-designed random clinical trials.
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SCLC

:   small cell lung cancer

PCI

:   prophylactic cranial irradiation

CRT

:   concurrent chemoradiotherapy

OS

:   overall survival

HR

:   hazard ratio

BM

:   brain metastases.
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###### 

Characteristics of studies included in the meta-analysis on the effect of PCI on overall survival in resected SCLC

  Author \[Ref\]    Year   Country   Design          Accrual years   Follow-up time            Total Patients   PCI (%)       Stage            PCI dose               Adjuvant chemotherapy
  ----------------- ------ --------- --------------- --------------- ------------------------- ---------------- ------------- ---------------- ---------------------- --------------------------------------------------------------------------------
  Bischof [@B27]    2007   Germany   Retrospective   1995-2006       29 (2-110) months         39               21 (54.0%)    p-stage IA-IIB   30Gy/15F               35 (90.0%) received ≥ 4 cycles of ChT
  Zhu H[@B16]       2014   China     Retrospective   2003-2009       39.4 (4.0-96.8) months    193              67 (34.7%)    c-stage I-III    25Gy/10F               All the patients received ChT, 164 (85.0%) patients received ≥ 4 cycles of ChT
  Yokouchi [@B30]   2015   Japan     Retrospective   2003-2013       25.5 (0.4-130.9) months   156              13 (8.3%)     c-stage I-III    25Gy/10F or 30Gy/15F   100 (64.1%) received chemotherapy
  Xu J[@B17]        2016   China     Retrospective   2006-2014       Not reported              349              115 (32.9%)   c-stage I-III    Not reported           290 (83.1%) received ≥ 4 cycles of ChT
  Yang C[@B28]      2016   USA       Retrospective   2003-2011       Not reported              954              99 (10.3%)    p-stage I        Not reported           566 (59.3%) received chemotherapy
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